Aktis Oncology (NASDAQ:AKTS) Shares Up 12.3% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price rose 12.3% during trading on Thursday . The stock traded as high as $23.18 and last traded at $22.90. Approximately 197,425 shares traded hands during trading, a decline of 46% from the average daily volume of 368,199 shares. The stock had previously closed at $20.40.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th.

Aktis Oncology Price Performance

Insiders Place Their Bets

In related news, Director Helen Susan Kim bought 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the director owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the purchase, the insider owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 6,117,776 shares of company stock valued at $110,119,968 in the last quarter. 3.30% of the stock is currently owned by corporate insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.